Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by harnessing the liver’s natural immunology capabilities. The Company has several proprietary programs; the lead one is in an orphan disease and is expected to enter the clinic in 2019.
Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction, a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies and a co-development agreement with Evotec for a Type 1 diabetes program that is currently in pre-clinical testing.
Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.